1832 Asset Management’s Axsome Therapeutics AXSM Stock Holding History

1832 Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.85M	Sell	28,000 -115,800	-81%	-$25.1M	﹤0.01%	395
2026 Q1	$24.3M	Buy	143,800 +130,100	+950%	+$22.5M	0.02%	285
2025 Q4	$2.5M	Buy	+13,700	New	+$1.91M	﹤0.01%	500
2025 Q2	–	Sell	-363,200	Closed	-$42.4M	–	665
2025 Q1	$42.4M	Buy	+363,200	New	+$41.4M	0.04%	216
2023 Q1	–	Sell	-118,200	Closed	-$9.12M	–	889
2022 Q4	$9.12M	Buy	+118,200	New	+$7.07M	0.02%	356

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

1832 Asset Management's AXSM Position: Q2 2026 in Review

1832 Asset Management reduced its Axsome Therapeutics (AXSM) stake by 81% in Q2 2026, selling an estimated $25.1M and leaving 28,000 shares worth $6.85M. The position accounts for ﹤0.01% of the portfolio, ranked #395.

1832 Asset Management first reported a position in AXSM in Q4 2022 and has held it in 5 quarters since. The position peaked at $42.4M in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

1832 Asset Management held 28,000 shares of Axsome Therapeutics worth $6.85M as of Q2 2026.
1832 Asset Management sold 115,800 Axsome Therapeutics shares in Q2 2026, an estimated $25.1M.
Axsome Therapeutics made up ﹤0.01% of 1832 Asset Management's portfolio in Q2 2026, its #395 holding.
1832 Asset Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 5 quarters since.
1832 Asset Management's Axsome Therapeutics position peaked at $42.4M in Q1 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on 1832 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.